Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGFR | P43088 | 16/20 | 0.67 |
| ▸ | PTGER1 | P34995 | 7/20 | 0.67 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.67 |
| ▸ | SLCO2A1 | Q92959 | 1/20 | 0.60 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24226152 | 0.91 | PTGFR (0.67) | PTGFRPTGER1PTGER2SLCO2A1PTGER3 | |
| SCHEMBL14601634 | 0.88 | PTGFR (0.63) | PTGFRPTGER1PTGER2SLCO2A1PTGER3 | |
| SCHEMBL19152027 | 0.87 | PTGFR (0.66) | PTGFRPTGER1PTGER2SLCO2A1PTGER3 | |
| SCHEMBL23975177 | 0.87 | PTGFR (0.66) | PTGFRPTGER1PTGER2SLCO2A1PTGER3 | |
| SCHEMBL18939648 | 0.87 | PTGFR (0.66) | PTGFRPTGER1PTGER2SLCO2A1PTGER3 | |
| SCHEMBL7124363 | 0.85 | PTGFR (0.74) | PTGFRPTGER1PTGER2SLCO2A1PTGER3 | |
| SCHEMBL7124357 | 0.85 | PTGFR (0.74) | PTGFRPTGER1PTGER2SLCO2A1PTGER3 | |
| SCHEMBL21940493 | 0.84 | PTGFR (0.62) | PTGFRPTGER1PTGER2SLCO2A1PTGER3 | |
| SCHEMBL14624416 | 0.84 | PTGFR (0.62) | PTGFRPTGER1PTGER2SLCO2A1PTGER3 | |
| SCHEMBL14624750 | 0.84 | PTGFR (0.62) | PTGFRPTGER1PTGER2SLCO2A1PTGER3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3950672-A1 | METHOD FOR PRODUCING PKROSTAGLANDIN | Kyowa Pharma Chemical Co., Ltd. (JP) | 2022-02-09 | — | — | EP | disclosed |
| US-20180118676-A1 | NITRIC OXIDE DONATING DERIVATIVES OF LATANOPROST FREE ACID | NICOX S.A. (FR) | 2018-05-03 | — | — | US | disclosed |
| US-7157590-B2 | Chemical intermediate for vision defect drug | FINETECH LABORATORIES LTD. (IL) | 2007-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118676-A1 | NITRIC OXIDE DONATING DERIVATIVES OF LATANOPROST FREE ACID | PTGIS, NOS2, NOS1 | PTGFR 39/4885PTGER1 16/4885PTGER2 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.